Trial Profile
A 24-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Salmeterol (Primary) ; Umeclidinium (Primary) ; Umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms EMAX
- Sponsors GlaxoSmithKline; GSK
- 04 Aug 2021 Results of a prespecified analysis of the EMAX trial, published in the Advances in Therapy
- 20 May 2021 Results of post hoc analysis assessing cost-effectiveness of UMEC/VI versus UMEC or SAL from a UK payer perspective in patients with COPD and no exacerbation history in the EMAX trial presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 20 May 2020 Results of post hoc analysis investigating its corollary, the clinically important improvement (CII), which is a composite endpoint that requires concordant minimum clinically important differences (MCID) in ≥2 patient-reported outcomes (PROs), presented at the 116th International Conference of the American Thoracic Society.